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Abstract
Background: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by a progressive
loss of motor neurons. ALS patients, as well as animal models such as mice overexpressing mutant SOD1s, are
characterized by increased energy expenditure. In mice, this hypermetabolism leads to energy deficit and
precipitates motor neuron degeneration. Recent studies have shown that mutations in the gene encoding the
dynein heavy chain protein are able to extend lifespan of mutant SOD1 mice. It remains unknown whether the
protection offered by these dynein mutations relies on a compensation of energy metabolism defects.
Results: SOD1(G93A) mice were crossbred with mice harboring the dynein mutant Cramping allele (Cra/+ mice).
Dynein mutation increased adipose stores in compound transgenic mice through increasing carbohydrate
oxidation and sparing lipids. Metabolic changes that occurred in double transgenic mice were accompanied by the
normalization of the expression of key mRNAs in the white adipose tissue and liver. Furthermore, Dynein Cra
mutation rescued decreased post-prandial plasma triglycerides and decreased non esterified fatty acids upon
fasting. In SOD1(G93A) mice, the dynein Cra mutation led to increased expression of IGF-1 in the liver, increased
systemic IGF-1 and, most importantly, to increased spinal IGF-1 levels that are potentially neuroprotective.
Conclusions: These findings suggest that the protection against SOD1(G93A) offered by the Cramping mutation in
the dynein gene is, at least partially, mediated by a reversal in energy deficit and increased IGF-1 availability to
motor neurons.
Background
Amyotrophic lateral sclerosis (ALS) is a neurodegenera-
tive disease characterized by a progressive loss of motor
neurons in the motor cortex, brainstem and spinal cord.
ALS patients develop progressive muscle weakness and
paralysis leading to death 3 to 5 years after first symp-
toms. Despite most cases of ALS occur sporadically, 5%
are genetically inherited. Out of these familial forms of
ALS, a subset is caused by mutations in the gene encod-
ing the Cu/Zn-superoxide dismutase 1 (SOD1).
Studies on patients and transgenic mutant SOD1 mice
showed that ALS-linked neurodegeneration was usually
associated with defects in energy homeostasis [1].
Indeed, mutant SOD1 mice show a pronounced hyper-
metabolism characterized by weight loss, increased oxy-
gen consumption and an increased use of lipids stores
[2,3]. In sporadic ALS patients, hyperlipemia was asso-
ciated with increased survival [4,5]. The mechanisms by
which such changes in energy metabolism participate to
motor neuron degeneration remain unknown.
Recent studies have shown that mutations in cytoplas-
mic dynein heavy chain gene protect motor neurons
against death and extend survival of mutant SOD1 mice
[6-8]. Cytoplasmic dynein is the major molecular motor
responsible for retrograde axonal transport in neurons.
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gene, respectively called “legs at odd angles“ (Loa),
“Cramping“ (Cra) and “Sprawling“ (Swl) have been iden-
tified in ENU-induced mouse strains [9,10]. All three
mutations lie in the stem domain of dynein heavy chain
and the Loa mutation disrupts, at least partially, the
dynein complex [11]. In the nervous system, these muta-
tions lead to perinatal proprioceptive neuropathy
[8,10,12]. Cra/+ and Loa/+ mice are hyperactive [13,14],
and this is associated, at least in Cra/+ mice with striatal
atrophy and compromised neurite outgrowth of striatal
neurons [13]. Besides the nervous system, Cra/+ and
Loa/+ mice display a major phenotype in adipose tissues
[15]. Indeed, Cra/+ and Loa/+ mice show strikingly
increased adipose stores, along with compromised
thermogenesis. This is most likely due to defective
stimulated lipolysis [15].
The extension in lifespan offered by mutations in
dynein heavy chain gene has been attributed to several
mechanisms, including compensation of axonal trans-
port defects [6] and mitochondrial dysfunction [16], or
decreased excitotoxic glutamate input to motor neurons
due to degeneration of proprioceptive neurons [8]. In
this report we provide evidence that the dynein muta-
tion is able to revert the energy deficit characteristic of
ALS in mutant SOD1 mice. Interestingly, this is asso-
ciated with increased hepatic IGF-1 expression and
increased spinal IGF-1. Taking into account these
results, we propose that the mutation in dynein is able
to provide neuroprotection against SOD1-ALS through
complementary pathways.
Results
Dynein mutation compensates for energy deficit of early
symptomatic transgenic SOD1(G93A) mice
We hypothesized that the protection offered by dynein
mutation against SOD1(G93A) neurodegeneration was
linked to a compensation of the energy deficit of SOD1
(G93A) mice. To test this hypothesis, we crossbred SOD1
(G93A) mice with Cra/+ mice and studied the energetic
physiology of compound heterozygotes before any obvious
motor symptoms. At 16 weeks of age, SOD1(G93A) nor
Cra/SOD1(G93A) mice did not show obvious clinical
s i g n ss u c ha sg a i ti m p a i r m e n tb u tb o t hg r o u p so fS O D 1
(G93A) mice were lighter than wild type littermates. Body
weight deficit of Cra/SOD1(G93A) mice was less than
S O D 1 ( G 9 3 A )m i c e( n o ts h o w n )a sp r e v i o u s l ys h o w n[ 7 ]
and both groups displayed similar upregulation of the
denervation marker AchRa in the gastrocnemius muscle
compared to non-SOD1(G93A) animals (Figure 1A). This
early symptomatic age was selected for further studies.
Both groups of SOD1(G93A) mice showed decreased
weights of epididymary and retroperitoneal fat pads, but
Cra/SOD1(G93A) fat pads were larger than that of SOD1
(G93A) mice (Figure 1B-C). This was not due to increased
food intake since all groups displayed similar food intake
(data not shown). In all, these results demonstrate that the
Cramping mutation in the dynein heavy chain gene com-
pensated partially for SOD1(G93A) energy deficit in early
symptomatic animals.
Dynein mutation does not modify SOD1(G93A)
hypermetabolism
We next determined whether the Cramping dynein
mutation compensated for energy deficit through
decreased SOD1(G93A) linked hypermetabolism. For
this, we measured energy expenditure of the four groups
of mice. As previously shown [3], SOD1(G93A) animals
had a 15-20% increase in resting energy expenditure
(Figure 2A), and this hypermetabolism was unchanged by
Cramping dynein mutation. Furthermore, SOD1(G93A)
associated increased total energy expenditure was also
Figure 1 Dynein mutation increased adipose stores in early
symptomatic SOD1(G93A) mice. A- mRNA levels of alpha subunit
of the nicotinic acetylcholine receptor (AchRa) in gastrocnemius
muscles of wild type (+/+) and dynein mutant mice (Cra/+) bearing
SOD1(G93A) transgene (SOD1m, black columns) or not (Wt, empty
columns) *P < 0.05 versus Wt. mRNA levels were standardized using
18S ribosomal RNA as a control. N = 9 mice per group. B-C- Relative
weight of epididimary (EPI) and retroperitoneal (RP) white adipose
tissue fat pad with regard to body weight (B). The panel C shows
absolute weight (in mg) of EPI and RP in the same mice than in A.
*P < 0.05 versus Wt; #, p < 0.05 as indicated. N = 9 mice per group.
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in energy deficit was not provided by, for instance,
decreased activity. Thus, the protective potential of
Cramping dynein mutation was independent of a direct
modulation of global hypermetabolism. Closer examina-
tion of indirect calorimetry results revealed however that
oxygen consumption of SOD1(G93A) and Cra/SOD1
(G93A) but also Cra/+ mice were increased during the
nocturnal period as compared with +/+ littermates
(Figure 2B). The respiratory quotient of Cra/+ and Cra/
SOD1(G93A) mice was higher than that of +/+ and
SOD1(G93A) mice at the same period (Figure 2C-D).
Since oxidation of carbohydrates leads to a respiratory
quotient of 1, while oxidation of lipids leads to a respira-
tory quotient of 0.7 [17], these results show that the
dynein mutation leads to a shift in nutrient use during
activity towards preferential carbohydrate oxidation, and
thus sparing of lipids and increased fat pad weights.
Figure 2 Dynein mutation does not decrease global hypermetabolism but shifts energy metabolism of SOD1(G93A) mice towards
carbohydrate use. A- Total (left panel) and resting (right panel) energy expenditure of wild type (+/+) and dynein mutant mice (Cra/+) bearing
SOD1(G93A) transgene (SOD1m, black columns) or not (Wt, empty columns) *P < 0.05 versus Wt. Note that SOD1(G93A) mice are hypermetabolic
and that the dynein mutant genotype has no effect on this hypermetabolism. N = 9 mice per group. B- Energy expenditure of the same mice
than in A as a function of time. Mice bearing a Cra dynein mutation are denoted by empty symbols, and their corresponding controls by a filled
symbol. Mice bearing a SOD1(G93A) (SOD1m) transgene are labeled by a squared symbol and their controls by a circle. Note that in the diurnal
period, there are no differences between +/+ and Cra/+ mice but that the presence of a SOD1(G93A) transgene increases energy expenditure.
On the contrary, during nocturnal activity period, the presence of either Cra/+ mutation or SOD1(G93A) transgene increases energy expenditure.
N = 9 mice per group. C-D- Respiratory quotient of the same mice than in A. The four groups of mice are shown in two graphs for clarity
reasons. Mice non transgenic for SOD1(G93A) (SOD1m) are shown in panel C (filled symbols, +/+; empty symbols, Cra/+). Mice transgenic for
SOD1(G93A) are shown in panel D (filled symbols, +/+; empty symbols, Cra/+). Note that the presence of a dynein mutation increases respiratory
quotient in otherwise wild type mice, and even more potently in SOD1(G93A) mice.
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changes associated with SOD1(G93A) energy deficit
The decreased lipid oxidation in mice bearing the
Cramping mutation might be due to their blunted ability
to mobilize adipose stores as previously documented
[15]. We thus sought to determine whether the
increased fat pad weights also reflected a better meta-
bolic status of the mice. Fatty acid synthase (FAS)
expression in the liver and Lipoprotein lipase (LPL)
expression in white adipose tissue are well known for
their regulated expression as a function of nutritional
and hormonal cues [18-21]. Most notably, these two
genes are profoundly downregulated by energy deficit,
including starvation as well as in SOD1(G93A) mice.
Here, the Cramping dynein mutation was able to revert
these down-regulations in Cra/SOD1(G93A) mice
(Figure 3A-B). This increased expression of FAS was
associated with unchanged expression of beta-oxidation
enzymes such as CPT1A and MCAD or gluconeogenesis
e n z y m e ss u c ha sP E P C Ki nt h el i v e r( F i g u r e3 B ) .
However, expression levels of PPARa and PGC1a,t w o
critical players in the transcriptional control of liver
beta-oxidation were decreased by expression of SOD1
(G93A) and expression of PPARg was increased. The
Cramping dynein mutation reverted PPARa and PGC1a
downregulations and potentiated PPARg upregulation in
Cra/SOD1(G93A) mice (Figure 3B). A hallmark of
energy homeostasis defect in SOD1(G93A) mice is the
occurrence of decreased circulating triglycerides after
feeding [2]. Consistent with these studies, fed, but not
fasted; triglycerides were decreased in SOD1(G93A)
mice. The Cramping dynein mutation partially compen-
sated for this defect (Figure 3C). Upon fasting, non-
esterified fatty acids levels were decreased in SOD1
(G93A) mice, as a likely result of increased muscle
uptake [2,3], and this was fully reverted by the Cramp-
ing mutation (Figure 3D). The effect of dynein mutation
on metabolic gene expression was not observed in skele-
tal muscle, in which gene expression of MCAD, CPT1B
and PGC1a were unaffected by either SOD1(G93A) or
Figure 3 Dynein mutation reverts the systemic and molecular alterations associated with energy deficit in SOD1(G93A) mice. A- mRNA
levels of lipoprotein lipase (LPL) in the epididimary white fat pad of wild type (+/+) and dynein mutant mice (Cra/+) bearing SOD1(G93A)
transgene (SOD1m, black columns) or not (Wt, empty columns). *P < 0.05 versus Wt; #, p < 0.05 as indicated. Note that the SOD1(G93A)-
associated decreased expression of LPL in the EPI is rescued by the dynein mutation in compound SOD1(G93A)/Cra mice. N = 9 mice per group.
B- mRNA levels of fatty acid synthase (FAS), carnithine palmitoyl transferase 1A (liver form, CPT1A), Medium chain acyl CoA dehydrogenase
(MCAD), peroxisome-proliferator activated receptor alpha (PPARa), peroxisome-proliferator activated receptor gamma co-activator 1 alpha
(PGC1a), phosphoenolpyruvate carboxykinase (PEPCK) and peroxisome-proliferator activated receptor gamma (PPARg) in the liver of the same
mice than in A. *P < 0.05 versus Wt; #, p < 0.05 as indicated. Note that the SOD1(G93A)-associated decreased expression of FAS in the liver is
rescued by the dynein mutation in compound SOD1(G93A)/Cra mice. N = 9 mice per group. C- Circulating triglycerides levels in the same mice
than in A either in fed (right) or fasted conditions (left). Note that the SOD1(G93A) transgene leads to decreased fed triglycerides levels and that
this is partially reverted in compound SOD1(G93A)/Cra mice. N = 9 mice per group. D- Circulating non-esterified fatty acids (NEFAs) levels in the
same mice than in A in fasted conditions. Note that the SOD1(G93A) transgene leads to decreased fasted NEFAs levels and that this is fully
reverted in compound SOD1(G93A)/Cra mice. N = 9 mice per group. E- mRNA levels of carnithine palmitoyl transferase 1B (muscle form, CPT1A),
Medium chain acyl CoA dehydrogenase (MCAD), peroxisome-proliferator activated receptor gamma (PPARg) and peroxisome-proliferator
activated receptor gamma co-activator 1 alpha (PGC1a) in the gastrocnemius muscle of the same mice than in A. *P < 0.05 versus Wt. N = 9
mice per group.
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mutation not only compensates for energy deficit, but
also reverts systemic and molecular changes associated
with SOD1(G93A) energy deficit.
Dynein mutation increases neuroprotective IGF-1
We next turned to define potential underlying mechan-
isms linking energy deficit and motor neuron survival.
One candidate mechanism could involve IGF-1. Circu-
lating IGF-1 is a growth factor mainly produced by the
liver, but also, in lesser amounts, in other cell types,
including muscle, astrocytes and neurons. IGF-1 has
been reported to exert neuroprotective effects [22] and
to delay motor neuron loss in SOD1(G93A) mice after
administration in an early stage of the disease [23,24].
IGF-1 expression is known to be decreased upon energy
deficit [25]. In SOD1(G93A) mice, liver IGF-1 expres-
sion was decreased of about 30% (Figure 4A), a situation
similar to massive energy deficit triggered by 60% caloric
restriction [25]. Consistent with reversal of energy defi-
cit, the Cramping dynein mutation completely reverted
IGF-1 mRNA downregulation, and even increased it
(Figure 4A). Skeletal muscle IGF-1 mRNA levels were
unchanged as were mRNA levels of mechano- growth
factor, a muscle specific splice variant of IGF-1 [26]
(Figure 4B) suggesting that these changes in IGF-1
mRNA levels were restricted to the liver. We next
wanted to determine whether hepatic IGF-1 upregula-
tion translated into increased circulating IGF-1. In
SOD1(G93A) mice, plasma IGF-1 levels were surpris-
ingly unchanged, suggesting that other mechanisms,
including transcription in other cell types or regulated
translation of hepatic IGF-1 mRNA occurred [27].
Plasma IGF-1 levels were modestly increased in Cramp-
ing dynein mutant mice but not in Cra/SOD1(G93A)
mice (Figure 4C). IGF-1 is poorly but significantly trans-
ported throughout the blood brain barrier [28-30] in
normal conditions and its entry into the CNS is regu-
lated by neuronal activity [31]. Since the blood brain
barrier of SOD1(G93A) mice is disrupted [32,33], it is
plausible that an increased fraction of IGF-1 is retained
in the spinal cord of Cra/SOD1(G93A) mice. Indeed,
spinal IGF-1 was increased in Cramping dynein mutant
mice and this was further enhanced by the SOD1
(G93A) transgene (Figure 5A). IGF-1 mRNA levels were
unchanged in the spinal cord (Figure 5B) arguing
against the proposal that these increased spinal levels of
IGF-1 were due to increased local transcription. Last,
mRNA levels of MMP-9 were partially restored by the
Cramping dynein mutation (Figure 5C) consistent with
the hypothesis of increased IGF-1 transcytosis upon
dynein mutation. Thus, the dynein mutation increases
availability of IGF-1 to motor neurons in the spinal
cord. The increased systemic production of IGF-1 by
the liver might be the source of increased spinal IGF-1.
Such a mechanism could account for the neuroprotec-
tive effects of the dynein mutation towards SOD1
(G93A) pathology.
Discussion
Our current studies provide evidence that the Cramping
dynein mutation is able to revert at some point the
energy deficit of SOD1(G93A) mice, and to increase
IGF-1 levels in the spinal cord of SOD1(G93A) animals.
Figure 4 Dynein mutation increases liver IGF-1 expression. A- mRNA levels of Insulin-like growth factor (IGF-1) in the liver of wild type (+/+)
and dynein mutant mice (Cra/+) bearing SOD1(G93A) transgene (SOD1m, black columns) or not (Wt, empty columns) *P < 0.05 versus Wt; #, p
< 0.05 as indicated. N = 9 mice per group. B- mRNA levels of Insulin-like growth factor (IGF-1) and its muscle specific splice variant mechano-
growth factor (MGF) in the gastrocnemius muscle of wild type (+/+) and dynein mutant mice (Cra/+) bearing SOD1(G93A) transgene (SOD1m,
black columns) or not (Wt, empty columns). N = 9 mice per group. C- Serum IGF-1 levels in wild type (+/+) and dynein mutant mice (Cra/+)
bearing SOD1(G93A) transgene (SOD1m, black columns) or not (Wt, empty columns) #, p < 0.05 as indicated. Note that circulating IGF-1 levels
are increased in dynein mutant mice and that this increase is abolished in compound SOD1(G93A)/Cra mice. N = 9 mice per group.
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two complementary protective pathways are acting in
dynein mutant mice to provide the paradoxical protec-
tion towards SOD1(G93A) pathology.
Dynein mutation compensates for energy deficit of SOD1
(G93A) mice: a rationale explanation for a seemingly
paradoxical observation
This study stems from the seminal observation of a mod-
erate lifespan extension of SOD1(G93A) mice when bear-
ing either Loa or Cra mutation [6-8]. These studies
intiated a flurry of research to explain the seemingly para-
doxical observation that two distinct molecular injuries
that independently lead to ALS-like disease might yield a
better outcome than a single one. Indeed, dynein mutant
mice were initially thought to develop motor neuron
degeneration [9], and it appeared difficult to understand
how mutating dynein, and thus precipitating late onset
motor neuron degeneration, might protect against early
onset SOD1(G93A)-mediated neurodegeneration. Closer
examination of dynein mutant mice however refuted that
they displayed motor neuron degeneration [8,10,12]. In
the nervous system, these mice display a frank perinatal
sensory neuropathy, accompanied by mild striatal atrophy
in the absence of neurodegeneration [13]. Furthermore,
apart from this neuronal phenotype, dynein mutant mice
also develop a number of peripheral defects, especially in
brown and white adipose tissues, that are largely reminis-
cent of striatal degeneration diseases [15]. The peripheral
phenotype of dynein mutant mice was strikingly opposite
to that of SOD1(G93A) mice. Indeed, while dynein mutant
mice accumulate fats [15], SOD1(G93A) mice are leaner
and lose white fat pads with disease progression [3]. The
origin of this energy deficit is currently unknown but is
associated with increased energy expenditure. Moreover,
compensating energy deficit through high fat feeding alle-
viates motor neuron degeneration [3]. Importantly, these
observations are of great relevance for the human pathol-
ogy since lipemia is positively correlated with survival of
ALS patients and energy status appears as a widely docu-
mented prognostic factor [1]. In our hands, crossbreeding
of dynein mutant mice with SOD1(G93A) mice yielded
very similar effects as high fat feeding, by increasing
energy storage. Increased RQ during nocturnal period sug-
gests indirectly increased beta-oxidation, while our gene
expression analysis are consistent with increased diurnal
lipogenesis in compound Cra /SOD1(G93A) mice. Such a
metabolic picture is fully consistent with the observed
improved energy status. Thus, a straightforward interpre-
tation would be that the dynein mutant mediated injury
compensates mutant SOD1 injury through its effect on
energy homeostasis, thereby alleviating neurodegeneration.
Potential involvement of IGF-1 in dynein mutant
mediated protection
We further provide mechanistic insights into how the
dynein mutant peripheral phenotype might provide pro-
tection to motor neurons. Liver IGF-1 expression is
under the control of nutritional cues, and is for instance
decreased in starved animals [25]. Consistent with their
Figure 5 Dynein mutation increases potentially neuroprotective IGF-1. A- Spinal cord IGF-1 levels in wild type (+/+) and dynein mutant
mice (Cra/+) bearing SOD1(G93A) transgene (SOD1m, black columns) or not (Wt, empty columns) #, p < 0.05 as indicated. Note that spinal cord
IGF-1 levels are increased in dynein mutant mice and that this increase is stronger in compound SOD1(G93A)/Cra mice. N = 9 mice per group.
B- mRNA levels of Insulin-like growth factor (IGF-1) in the spinal cord of wild type (+/+) and dynein mutant mice (Cra/+) bearing SOD1(G93A)
transgene (SOD1m, black columns) or not (Wt, empty columns). N = 9 mice per group. C- mRNA levels of matrix metallo proteinase 9 (MMP9) in
the spinal cord of wild type (+/+) and dynein mutant mice (Cra/+) bearing SOD1(G93A) transgene (SOD1m, black columns) or not (Wt, empty
columns). *P < 0.05 versus Wt; #, p < 0.05 as indicated. N = 9 mice per group.
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in SOD1(G93A) liver, and this was fully reverted by
dynein mutation. It should be noted however that SOD1
(G93A) showed only limited analogy with starved ani-
mals since liver expression of genes such as PPARa or
PGC1a showed regulations opposite to those observed
in starved animals. In double mutant mice, while there
were no changes in circulating IGF-1, we observed
increased spinal IGF-1. A similar trend was observed
between wild type and SOD1(G93A) animals. One may
consider that the increased hepatic production of IGF-1,
due to the reversal of the energy deficit of SOD1(G93A)
mice, is directed towards the nervous system, and thus
motor neurons, of SOD1(G93A) mice. This is consistent
with our results at the different levels at which we inves-
tigated IGF-1 (liver, skeletal muscle, plasma and spinal
cord). This interpretation is further in line with modi-
fied expression of IGF-1 receptors and IGF-1 binding
proteins that occur in SOD1(G93A) mice motor neu-
rons [34,35]. It should be noted here that circulating,
liver derived IGF-1 is able to cross the blood brain bar-
rier (BBB) and counteract age-related decline in cogni-
tive functions [36,37]. This natural entry might even be
potentiated by leakage of the BBB during ALS disease
[32,33]. Also, IGF-1 transcytosis has been shown to be
dependent upon neuronal activity, which leads to
increased MMP-9 activation and cleavage of IGF bind-
ing proteins [31]. Interestingly, we previously observed
increased activity of MMP-9 in SOD1(G93A) spinal
cord [38] and others have documented decreased levels
of IGF binding proteins [35] in SOD1(G93A) CNS.
Decreased MMP9 mRNA levels in sick SOD1(G93A)
m i c ei sn o ta to d d sw i t hp r e v i o u sr e s u l t ss i n c ew ea n d
others have shown that MMP9 activity actually peaks
before onset and then decreases [38,39]. In all, our
results support that IGF-1 transcytosis might be
increased in SOD1(G93A), and to an even greater extent
in Cra/SOD1(G93A) mice.
Our study does not directly address whether
increased IGF-1 is responsible for the extension in life-
span. This is however plausible as most studies
observed protective effect of increasing IGF-1 in SOD1
(G93A) mice [23,24]. A direct positive impact on neu-
romuscular junctions from circulating IGF-1 cannot be
excluded since muscle-restricted expression of IGF-1 is
able to stabilize neuromuscular junctions and delay
motor neurons death of SOD1(G93A) G93A mice [24].
Also, IGF-1 is able to provide protection to mitochon-
dria even at low doses in aging rats [40,41] through a
boost in mitochondrial biogenesis and our results are
thus consistent with the recent observation of mito-
chondrial protection in SOD1(G93A) mice by dynein
mutation [16]. In human clinical trials however, IGF-1
did not achieve efficacy in ALS clinical trials [42]. This
lack of efficacy might be due to inappropriate targeting
of IGF-1 to motor neurons (see below). Alternatively,
IGF-1 might be acting in combination with other still
unknown circulating factors to provide full protection
in dynein mutant mice. In all, we propose that circu-
lating factors modified by the reversal of energy deficit,
and between these, IGF-1, contribute to the protection
offered by dynein mutation.
Mutant dynein mediated protection may rest on two
complementary biological events
Several research groups, including ours, have previously
shown that dynein Cra and Loa mutations were able to
increase the lifespan of SOD1G93A mice. Several
mechanisms have been proposed to explain the underly-
ing mechanisms of mutant dynein protection towards
mutant SOD1 pathogenesis. To conclude, we would like
here to discuss critically these different hypotheses in
the light of our results and provide a working model
summarizing these different potential mechanisms.
In the first study, Kieran et al. [6] suggested a cell
autonomous effect of dynein mutation in motor neurons
and proposed that the defect in retrograde transport
triggered by mutant dynein counterbalanced the one
due to SOD1(G93A) in the anterograde direction, and
thereby restoring axonal homeostasis. This cell autono-
mous protective effect of dynein mutation is in line with
results obtained by Teuling and collaborators [43] that
used neuron-specific overexpression of an N-terminal
deleted form of BicD2 to modulate dynein/cargo inter-
action [44]. Interestingly, BicD2 overexpression in neu-
rons disrupted retrograde axonal transport, delayed the
SOD1 aggregates retrograde transport toward the cell
center and increased survival of SOD1 G93A mice [43].
However, BicD2 overexpression might also have a num-
ber of dynein independent effects, including on kinesin-
mediated transport [45] Pan-neuronal overexpression of
BicD2 might also lead to impairment of neuronal phy-
siology in neurons other than motor neurons, including
in proprioceptive neurons (see below). Thus, the
hypothesis of the restoration of axonal homeostasis by
double blockade of both anterograde and retrograde
directions of axonal transport remains unproven.
The complex phenotype of dynein mutant mice render
very plausible that dynein mutation could also act at
multiple levels besides motor neurons. First, dynein
mutation is likely to reduce glutamate excitotoxicity
through the degeneration of proprioceptive glutamate
inputs to motor neurons [8]. Although this hypothesis is
initially attractive, type Ia afferents that degenerate in
dynein mutant mice stimulate also inhibitory interneur-
ons to perform reciprocal inhibition [46]. The exact
effect of dynein mutation on excitotoxic load on motor
neurons thus remains to be investigated. Besides
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to be increased in dynein mutant mice due to increased
spontaneous activity [13]. Our current findings lead us
to propose that the protective dynein mutations, such as
Legs at odd angles and Cramping, also impact bioener-
getics’ mechanisms and revert the energy deficit of
SOD1(G93A) mice. In the compound mice, this leads to
increased production of IGF-1. We propose that the
proprioceptive degeneration and CNS linked hyperactiv-
i t yc o n v e r g et om o d i f yn e u r o n a la c t i v i t ya n df a c i l i t a t e
the net transcytosis of IGF-1 in the vicinity of motor
neurons, thus achieving neuroprotection. This working
model is summarized in Figure 6.
Conclusions
These findings suggest that the protection against SOD1
(G93A) offered by the Cramping mutation in the dynein
gene is, at least partially, mediated by a reversal in
energy deficit and increased IGF-1 availability to motor
neurons. Our study provides a rationale explanation to
increased survival in double dynein mutant/SOD1
(G93A) mice and suggests that the neuroprotection
results from dynein mutant phenotype in various tissues.
Methods
Animals
Heterozygous Cra/+ females were crossed with SOD93A
males and were identified by tail DNA genotyping for
the human transgene SOD1 (G93A) and the Cra muta-
tion as described previously [7,9]. Experiments were per-
formed with littermates mice with 9 mice per group.
Mice were maintained at 23°C with a 12h light/dark
cycle and had food and water ad libitum. All animal
experiments were performed under the supervision of
authorized investigators and followed current EU regula-
tions. Animals were treated in accordance with the Eur-
opean Union guide for the care and the use of animals
in research (commission June 18th 2007, 2007/526/CE).
Figure 6 a working model for dynein mutant protection against SOD1-ALS. We propose that dynein mutations provide neuroprotection by
converging paths. First, degeneration of proprioceptive neurons (PN) modify network activity (1) by decreasing direct glutamatergic input to
motor neurons (MN), but also to inhibitory interneurons (IN). Second, CNS-linked hyperactivity (2) might on its own lead to increased
motoneuronal activity, and MMP9 activation. Last, by modifying energy metabolism and favoring carbohydrate oxidation over lipid oxidation (3),
dynein mutation reverts the energy deficit of SOD1(G93A) mice, thereby increasing IGF-1 production in the liver. This increased IGF-1 production
is able to enter the CNS due to MMP9 activation. Other circulating factors might also increase IGF-1 supply to motor neurons.
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Page 8 of 11LD has been allowed to perform mouse experiments
(agreement A67-266, direction des services vétérinaires,
Strasbourg, Bas-Rhin, France).
Indirect calorimetry
We measured O2 consumption and CO2 production by
using an open-circuit indirect calorimetry system (Sable
systems, Las Vegas, USA). Concentrations of O2 and
CO2 in the outgoing air were successively measured in
five different cages. The system was rinsed for 90 s
between each measurement. Final values of gas concen-
trations were the mean of 10 measures obtained during
40 s. Each cage was sampled every 11 min, and one
cage was left vacant as reference of ambient gas concen-
trations. Measurements were performed continuously
over 23 1/2 h, a 30-min period being required for cali-
bration of the O2 and CO2 analyzers. In total, 127 mea-
sures were collected per day and mouse. The average of
the five lowest values of O2 consumption was consid-
ered as resting energy expenditure. Energy expenditure
was obtained by using an energy equivalent of 20.1 J/ml
O2. The respiratory quotient was the ratio of CO2 pro-
duction over O2 consumption.
RT-qPCR
RNA were extracted by using Trizol
® (Invitrogen,
Cergy-Pontoise, France). Real time RT quantitative PCR
was performed with one microgramme of total RNA as
described [13]. PCR analysis was carried out on a Bio-
Rad iCycler System using iQSYBR Green Supermix. A
specific standard curve was performed in parallel for
each gene, and each sample was quantified in duplicate.
PCR conditions were 3 min at 94°C, followed by 40
cycles of 45 s at 94°C and 10 s at 60°C. The relative
levels of each RNA were normalized to 18S RNA levels.
Oligonucleotide sequences are reported in the table 1.
Biochemical assays
Mouse IGF-1 levels were measured using Mouse/Rat
IGF-I Quantikine ELISA Kit (R&D systems), using man-
ufacturer’s instructions. Plasma triglycerides and NEFAs
were measured using Randox kits using manufacturer’s
instructions.
Statistical Analysis
Statistical comparisons were accomplished with the
unpaired Student t test, unless otherwise indicated, or
ANOVA followed by the post hoc Newman-Keuls mul-
tiple comparisons test usingP R I S Mv e r s i o n2 . 0 as o f t -
ware (GraphPad, San Diego).
List of abbreviations
AchRα: alpha subunit of the nicotinic cholinergic receptor; ALS: amyotrophic
lateral sclerosis; BBB: blood brain barrier; BicD2: bicaudal D2; CNS: central
nervous system; Cra: Cramping mutation of the Dyn1hc1 gene; FAS: fatty
acid synthase; IGF-1: Insulin-like growth factor 1; LPL: lipoprotein lipase;
SOD1: copper-zinc superoxide dismutase.
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